Evaluating Caenorhabditis elegans as a Toxicity Model for Reuptake Inhibitors

Christopher E Hernandez1, Alexandra Van Stone2, Christopher So1

  • 1College of Pharmacy, Roseman University of Health Sciences, Henderson, Nevada, United States.

Insights

The nematode worm, Caenorhabditis elegans, can prescreen selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) drug toxicity. However, C. elegans responses do not fully replicate mammalian outcomes, limiting its use as a replacement for animal testing.

Area of Science:

  • Pharmacology
  • Toxicology
  • Model Organisms

Background:

  • Drug toxicity evaluation is critical in pharmaceutical development.
  • Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are widely prescribed antidepressants.
  • Invertebrate models offer potential for rapid and cost-effective toxicity screening.

Purpose of the Study:

  • To investigate the utility of Caenorhabditis elegans as a model for assessing the toxicity of SSRIs and SNRIs.
  • To compare the toxicity profiles of select SSRIs and SNRIs in C. elegans with known mammalian responses.

Main Methods:

  • Utilized C. elegans as an invertebrate model system.
  • Assessed drug toxicity by measuring drug-induced non-responsiveness.
  • Evaluated a panel of SSRIs and SNRIs for their toxic effects in C. elegans.

Main Results:

  • C. elegans exhibited differential toxicity responses to SSRIs and SNRIs.
  • Observed conserved trends in toxicity for some drugs, such as escitalopram > citalopram and duloxetine > milnacipran.
  • Desvenlafaxine induced toxicity in C. elegans, whereas venlafaxine did not.

Conclusions:

  • C. elegans demonstrates potential as a rapid, low-cost prescreening tool for SSRI and SNRI toxicity.
  • The C. elegans model does not fully recapitulate mammalian toxicity profiles, indicating it cannot replace established mammalian testing.
  • Further research may refine the use of C. elegans for early-stage drug safety assessment.

Related Concept Videos